Page 91 - 《中国药房》2024年15期
P. 91
sectable hepatocellular carcinoma (CARES-310):a ran‐ meta-analysis research methodological advances series:
domised,open-label,international phase 3 study[J]. Lan‐ 13:network meta-analysis of survival data[J]. Chin J Evid
cet,2023,402(10408):1133-1146. Based Cardiovasc Med,2021,13(6):649-652.
[10] KUDO M. Durvalumab plus tremelimumab in unresec- [18] 唐密,杨燕,胡善联,等. 多准则决策分析应用于卫生决
table hepatocellular carcinoma[J]. Hepatobiliary Surg 策的理论基础与进展[J]. 中国卫生资源,2020,23(4):
Nutr,2022,11(4):592-596. 326-331.
[11] 黄倩倩,王涛,康琪,等. 多准则决策分析在药物效益风 TANG M,YANG Y,HU S L,et al. Theoretical basis and
险评价领域的应用研究进展[J]. 中国新药杂志,2021,30 progress of multi-criteria decision analysis in healthcare
(22):2069-2074. decision-making[J]. Chin Health Resour,2020,23(4):
HUANG Q Q,WANG T,KANG Q,et al. Research pro- 326-331.
gress in application of multi-criteria decision analysis in [19] FINN R S,QIN S K,IKEDA M,et al. Atezolizumab plus
the field of drug benefit-risk assessment[J]. Chin J N bevacizumab in unresectable hepatocellular carcinoma[J].
Drugs,2021,30(22):2069-2074. N Engl J Med,2020,382(20):1894-1905.
[12] MORENO-CALDERÓN A,TONG T S,THOKALA P. [20] YAU T,PARK J W,FINN R S,et al. Nivolumab versus
Multi-criteria decision analysis software in healthcare sorafenib in advanced hepatocellular carcinoma (Check‐
priority setting:a systematic review[J]. Pharmacoeconomics, Mate 459):a randomised,multicentre,open-label,phase 3
2020,38(3):269-283. trial[J]. Lancet Oncol,2022,23(1):77-90.
[13] DAI Z Q,XU S M,WU X,et al. Knowledge mapping of [21] LIU K,ZHU Y W,ZHU H. Immunotherapy or targeted
multicriteria decision analysis in healthcare:a bibliometric therapy as the first-line strategies for unresectable hepato‐
analysis[J]. Front Public Health,2022,10:895552. cellular carcinoma:a network meta-analysis and cost-
[14] 何 玉 梅 ,聂 智 峰 ,李 薇 ,等 . 多 准 则 决 策 分 析 中 的 effectiveness analysis[J]. Front Immunol,2023,13:
MACBETH方法与软件简介[J]. 医学新知,2023,33(2): 1103055.
110-119. [22] LI L,YANG S L,CHEN Y W,et al. Immune checkpoint
HE Y M,NIE Z F,LI W,et al. Introduction to inhibitors plus an anti-VEGF antibody as the first-line
MACBETH methods and software in multi-criteria deci‐ treatment for unresectable hepatocellular carcinoma:a net‐
sion analysis[J]. N Med,2023,33(2):110-119. work meta-analysis and cost-effectiveness analysis[J].
[15] 国家卫生健康委员会医政医管局 . 原发性肝癌诊疗指 Front Pharmacol,2022,13:891008.
南 :2022 年 版 [J]. 中 华 肝 脏 病 杂 志 ,2022,30(4): [23] VERMERSCH P,MARTINELLI V,PFLEGER C,et al.
367-388. Benefit-risk assessment of cladribine using multi-criteria
Department of Medical Administration,National Health decision analysis (MCDA) for patients with relapsing-
Commission. Standardization for diagnosis and treatment remitting multiple sclerosis[J]. Clin Ther,2019,41(2):
of hepatocellular carcinoma:2022 edition[J]. Chin J Hepa‐ 249-260.e18.
tol,2022,30(4):367-388. [24] SU D,WU B,SHI L. Cost-effectiveness of atezolizumab
[16] 王汝龙. 中国药品综合评价指南参考大纲:第二版第七 plus bevacizumab vs sorafenib as first-line treatment of
章:药物临床价值综合评价指南[J]. 药品评价,2015,12 unresectable hepatocellular carcinoma[J]. JAMA Netw
(8):19-20. Open,2021,4(2):e210037.
WANG R L. Reference outline of comprehensive evalu- [25] ZHAO M Y,PAN X M,YIN Y,et al. Cost-effectiveness
ation guidelines for drugs in China:chapter Ⅶ of second analysis of five systemic treatments for unresectable hepa‐
edition:comprehensive evaluation guidelines for clinical tocellular carcinoma in China:an economic evaluation
value of drugs[J]. Drug Eval,2015,12(8):19-20. based on network meta-analysis[J]. Front Public Health,
[17] 张天嵩,董圣杰,杨智荣,等. 网络Meta分析研究进展系 2022,10:869960.
列:十三:生存数据的网络 Meta 分析[J]. 中国循证心血 (收稿日期:2024-01-21 修回日期:2024-06-19)
管医学杂志,2021,13(6):649-652. (编辑:陈 宏)
ZHANG T S,DONG S J,YANG Z R,et al. Network
中国药房 2024年第35卷第15期 China Pharmacy 2024 Vol. 35 No. 15 · 1881 ·